In July 2010, we initiated coverage of Aastrom Biosciences (NASDAQ:ASTM) with a Neutral rating and a $2.50 price target. Aastrom is pioneering the research effort on adult stem cells for therapeutic applications, specifically for the treatment of cardiovascular diseases such as critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). Aastrom’s approach involves expansion of a patient’s ...